BioCentury | Jul 7, 2014
Financial News

Abzena raises L20 million in London IPO

...trading is slated for Thursday. The company comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...
BioCentury | Jun 23, 2014
Finance

Abzena's AIM

...two biologics services companies: PolyTherics Ltd. and Antitope Ltd. Burt said the pair provide complementary services: PolyTherics...
BioCentury | Jun 17, 2014
Financial News

Service/technology provider Abzena files for London IPO

...Exchange underwritten by Cenkos Securities plc. Abzena comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...
BioCentury | Jun 16, 2014
Company News

Abzena, Alpha Cancer deal

...Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will...
...has exclusive, worldwide rights to recombinant human AFP from Merrimack Pharmaceuticals Inc. (NASDAQ:MACK, Cambridge, Mass.). PolyTherics...
BioCentury | Jun 2, 2014
Company News

Abzena antibodies, drug delivery news

...Ltd. and said Abzena comprises two subsidiaries - PolyTherics and Antitope. The company will move PolyTherics'...
...Ltd., which continued to operate as a subsidiary of PolyTherics (see BioCentury, Aug. 5, 2013). PolyTherics...
BioCentury | Apr 21, 2014
Company News

MacroGenics, PolyTherics deal

...PolyTherics and MacroGenics extended a 2010 deal to develop antibody-drug conjugates (ADCs). Under the extension, PolyTherics...
...original deal, PolyTherics used its TheraPEG technology to extend the half-life of the DART antibodies. PolyTherics...
...technology to develop resulting antibodies. PolyTherics is eligible for undisclosed milestones, plus single-digit percentage royalties. PolyTherics...
BioCentury | Dec 16, 2013
Company News

Annexon, PolyTherics deal

...Annexon partnered with PolyTherics' Antitope Ltd. subsidiary to generate antibodies to treat neurodegenerative diseases. Annexon will...
...developed. The partners declined to disclose financial details. Annexon Inc. , South San Francisco, Calif. PolyTherics Ltd....
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...Spirogen's ADC technology: the Genentech Inc. unit of Roche , Seattle Genetics, Ablynx N.V. and PolyTherics Ltd....
...NYSE:AZN), London, U.K. Genentech Inc. , South San Francisco, Calif. MedImmune LLC , Gaithersburg, Md. PolyTherics Ltd....
BioCentury | Oct 21, 2013
Company News

PolyTherics, Tube Pharmaceuticals deal

...PolyTherics and Tube partnered to develop antibody-drug conjugates (ADCs) to treat cancer using PolyTherics' ThioBridge conjugation...
...to develop in-house. The partners also plan to conduct preclinical testing of ADC candidates that PolyTherics...
...revenues arising from licensing deals but declined to disclose financial terms (see BioCentury, Aug. 5). PolyTherics Ltd....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...to serve as a conjugation point for cytotoxic agents. Another company in this space is PolyTherics Ltd....
...Cambridge, Mass. Millennium Pharmaceuticals Inc. , Cambridge, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. PolyTherics Ltd....
...for non-covalent conjugation of peptide linked to a payload NA (drug discovery not started yet) PolyTherics Ltd....
Items per page:
1 - 10 of 40
BioCentury | Jul 7, 2014
Financial News

Abzena raises L20 million in London IPO

...trading is slated for Thursday. The company comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...
BioCentury | Jun 23, 2014
Finance

Abzena's AIM

...two biologics services companies: PolyTherics Ltd. and Antitope Ltd. Burt said the pair provide complementary services: PolyTherics...
BioCentury | Jun 17, 2014
Financial News

Service/technology provider Abzena files for London IPO

...Exchange underwritten by Cenkos Securities plc. Abzena comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...
BioCentury | Jun 16, 2014
Company News

Abzena, Alpha Cancer deal

...Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will...
...has exclusive, worldwide rights to recombinant human AFP from Merrimack Pharmaceuticals Inc. (NASDAQ:MACK, Cambridge, Mass.). PolyTherics...
BioCentury | Jun 2, 2014
Company News

Abzena antibodies, drug delivery news

...Ltd. and said Abzena comprises two subsidiaries - PolyTherics and Antitope. The company will move PolyTherics'...
...Ltd., which continued to operate as a subsidiary of PolyTherics (see BioCentury, Aug. 5, 2013). PolyTherics...
BioCentury | Apr 21, 2014
Company News

MacroGenics, PolyTherics deal

...PolyTherics and MacroGenics extended a 2010 deal to develop antibody-drug conjugates (ADCs). Under the extension, PolyTherics...
...original deal, PolyTherics used its TheraPEG technology to extend the half-life of the DART antibodies. PolyTherics...
...technology to develop resulting antibodies. PolyTherics is eligible for undisclosed milestones, plus single-digit percentage royalties. PolyTherics...
BioCentury | Dec 16, 2013
Company News

Annexon, PolyTherics deal

...Annexon partnered with PolyTherics' Antitope Ltd. subsidiary to generate antibodies to treat neurodegenerative diseases. Annexon will...
...developed. The partners declined to disclose financial details. Annexon Inc. , South San Francisco, Calif. PolyTherics Ltd....
BioCentury | Oct 21, 2013
Strategy

MedImmune's warheads

...Spirogen's ADC technology: the Genentech Inc. unit of Roche , Seattle Genetics, Ablynx N.V. and PolyTherics Ltd....
...NYSE:AZN), London, U.K. Genentech Inc. , South San Francisco, Calif. MedImmune LLC , Gaithersburg, Md. PolyTherics Ltd....
BioCentury | Oct 21, 2013
Company News

PolyTherics, Tube Pharmaceuticals deal

...PolyTherics and Tube partnered to develop antibody-drug conjugates (ADCs) to treat cancer using PolyTherics' ThioBridge conjugation...
...to develop in-house. The partners also plan to conduct preclinical testing of ADC candidates that PolyTherics...
...revenues arising from licensing deals but declined to disclose financial terms (see BioCentury, Aug. 5). PolyTherics Ltd....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...to serve as a conjugation point for cytotoxic agents. Another company in this space is PolyTherics Ltd....
...Cambridge, Mass. Millennium Pharmaceuticals Inc. , Cambridge, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. PolyTherics Ltd....
...for non-covalent conjugation of peptide linked to a payload NA (drug discovery not started yet) PolyTherics Ltd....
Items per page:
1 - 10 of 40